secwatch.observer — SEC 8-K summary
======================================

Issuer:     Journey Medical Corp (DERM)
CIK:        0001867066
Form:       8-K
Filed at:   2023-05-22T23:59:59+00:00
Accession:  0001104659-23-063145
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 2.02, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Journey Medical Q1 net loss $10.1M on revenue decline; DFD-29 topline expected June 2023
--------------------------------------------------------------------------------

- Net product revenue $12.2M, down from $20.8M YoY, due to higher gross-to-net adjustments and lower Qbrexza, Targadox, Ximino sales.
- Net loss $10.1M ($0.57/share) vs. net loss $1.4M ($0.08/share) in Q1 2022; Adjusted EBITDA -$5.3M.
- DFD-29 Phase 3 last patient out achieved; topline data expected June 2023; NDA filing planned H2 2023.
- SG&A expenses cut to $13.3M (-10% YoY); additional annual savings >$12M vs. 2022 expected from cost reduction initiative.
- Fifth Amendment to East West Bank facility: $10M term loan repaid, maturity extended to July 2024, covenants removed except minimum liquidity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867066/000110465923063145/0001104659-23-063145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867066/000110465923063145/tm2315269d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-063145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer